Acorda Therapeutics Inc (ACOR)

Overview

Acorda Therapeutics, Inc. is a distinguished biopharmaceutical company based in the United States, specifically headquartered in Pearl River, New York. Founded in 1995, the company stands out for its innovative approach to developing and commercializing a range of therapies aimed at addressing neurological disorders. With a focus on improving the quality of life for people living with conditions such as multiple sclerosis and Parkinson's disease, Acorda Therapeutics has made significant strides in the biopharmaceutical industry. Their commitment to leveraging scientific advances has positioned them as key players in the market, with a pipeline of promising drugs and collaborations that underscore their potential for contributing meaningfully to neurological health care.

Products and Services

• Ampyra (dalfampridine)

An oral drug that marks a significant advancement in the treatment of multiple sclerosis, Ampyra is designed to improve walking capabilities in adults diagnosed with this neurological condition. Fully approved and available in the United States, its active ingredient, dalfampridine, enhances nerve signal conduction in damaged areas, offering patients a better quality of life through improved mobility.

• Inbrija (inhaled levodopa)

Inbrija represents a novel approach to treating Parkinson's disease, especially targeting the OFF periods patients experience when the effects of their standard carbidopa/levodopa regimen wear off. This inhaled version of levodopa provides a rapid onset of action, allowing for quicker relief from symptoms and a smoother control over the disease's fluctuating nature.

• Fampyra

As the international brand name for Ampyra, Fampyra extends the reach of Acorda Therapeutics’ flagship product beyond the United States. Available in Europe, Asia, and the Americas, it signifies the global commitment of the company to enhance mobility in people affected by multiple sclerosis through the same proven mechanism of action.

• Cimaglermin alfa (GGF2)

Currently in Phase 1 clinical trials, Cimaglermin alfa (GGF2) exemplifies the forward-looking research being conducted by Acorda Therapeutics. This neuregulin growth factor family member is under investigation for its potential to not only aid in the recovery from neurological injuries but also to improve heart function in animal models of heart failure, marking an exciting frontier in the treatment of neurological and cardiovascular conditions.